Biofrontera Inc. (BFRI) News

Biofrontera Inc. (BFRI): $0.76

0.02 (-2.68%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

D

Filter BFRI News Items

BFRI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest BFRI News From Around the Web

Below are the latest news stories about BIOFRONTERA INC that investors may wish to consider to help them evaluate BFRI as an investment opportunity.

Biofrontera Inc. (BFRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Biofrontera Inc. (BFRI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Yahoo | November 22, 2023

Biofrontera Inc. (NASDAQ:BFRI) Q3 2023 Earnings Call Transcript

Biofrontera Inc. (NASDAQ:BFRI) Q3 2023 Earnings Call Transcript November 10, 2023 Operator: Good day, and welcome to the Biofrontera Inc. Third Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Tirth Patel with LHA Investor Relations. […]

Yahoo | November 11, 2023

Benign Growth For Biofrontera Inc. (NASDAQ:BFRI) Underpins Stock's 50% Plummet

To the annoyance of some shareholders, Biofrontera Inc. ( NASDAQ:BFRI ) shares are down a considerable 50% in the last...

Yahoo | November 11, 2023

Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update

Conference call begins at 10:00 a.m. Eastern time on Friday, November 10, 2023WOBURN, MA / ACCESSWIRE / November 9, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic ...

Yahoo | November 9, 2023

Biofrontera Inc. (BFRI) Upgraded to Buy: Here's What You Should Know

Biofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | November 9, 2023

Biofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10

WOBURN, MA / ACCESSWIRE / November 3, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended ...

Yahoo | November 3, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time for another busy day of trading as we go over the biggest pre-market stock movers worth watching on Tuesday morning!

William White on InvestorPlace | October 31, 2023

Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules

WOBURN, MA / ACCESSWIRE / October 31, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, entered into a securities purchase agreement ...

Yahoo | October 31, 2023

Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)

Patent Application Filed with Potential to Extend Ameluz® Protection to 2043WOBURN, MA / ACCESSWIRE / October 10, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization ...

Yahoo | October 10, 2023

Biofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference

WOBURN, MA / ACCESSWIRE / October 5, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced management will deliver a company ...

Yahoo | October 5, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!